tbuckley/cabot-search huggingface dataset:
302P Increased eosinophil may be predictor for efficacy and safety in patient with renal cell carcinoma treated with ipilimumab plus nivolumab: A retrospective multicenter study
Authors: Y. Tasaki, S. Hamamoto, S. Yamashita, J. Furukawa, K. Fujita, R. Tomida, M. Miyake, H. Iwamoto, N. Ito, I. Nanami, Y. Kimura, K. Odagiri, M. Iida, M. Yoshihisa, S. Yosuke, Y. Hotta, K. Taguchi, T. Naiki, T. Yasui, Y. Hibi
Journal: Annals of Oncology (2024)
290P Impact of SBRT in oligometastatic renal cell carcinoma: A spotlight on the unexplored
Authors: A. Radha P, S.P. Susheela, P. Damodara, M. Gupta, V. Gupta, S.S. Gopireddy, S. Manjunath, K. M, M. Begum, S. Sowry, S. Patil, K. Kallur
Journal: Annals of Oncology (2024)
372O Balstilimab (bal) alone or with zalifrelimab (zal) treatment for cervical cancer: An open-label, non-comparative, randomised, phase II trial
Authors: L. Wu, H. Qiu, L. Zhu, S. Wei, J. Chen, S. Liao, R. An, S. Li, M. Feng, J. Zhang, Y. Wu, W. Tao, Q. Li, X. Chen, M. Zhang, J. Wang, H. Xiong, J. An, P. Li, L. Ding
Journal: Annals of Oncology (2024)
216P Long-term outcomes of a multicenter phase II trial evaluating the efficacy of preoperative lenvatinib therapy for patients with advanced hepatocellular carcinoma
Authors: A. Ichida, J. Arita, M. Tada, E. Hatano, S. Eguchi, A. Saiura, H. Nagano, J. Shindoh, M. Hashimoto, N. Takemura, K. Taura, Y. Sakamoto, Y. Takahashi, Y. Seyama, Y. Sasaki, K. Uemura, N. Kokudo, K. Hasegawa
Journal: Annals of Oncology (2024)
366P Clinicopathological predictors of favourable response to docetaxel in patients with metastatic castration-resistant prostate cancer
Authors: G. Bentick, A. Balasubramanian, A. Anton, A. Azad, S. Brown, J.C.H. Goh, S.S.L. Wong, P. Parente, J. Shapiro, E.C.H. Liow, J. Torres, A. Smith, C. Steer, M. Warren, P. Gibbs, B. Tran, A.J. Weickhardt
Journal: Annals of Oncology (2024)
129MO Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive (HER2+) advanced gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric06 (DG-06) final analysis
Authors: L. Shen, P. Chen, J. Lu, Y. Wan, Y. Zheng, F. Ye, J. Yang, Y. Liu, H. Pan, H. Chen, M.L. Sun, Q. Fan, Y. Yuan, K. Chen, Z. Sun, H. Tian, X. Ye, Z. Peng
Journal: Annals of Oncology (2024)
200P Final analysis of the ELIXIR study: A prospective, multicenter, observational study to evaluate the efficacy and safety of atezolizumab + bevacizumab (Atezo+Bev) in Japanese patients with unresectable hepatocellular carcinoma (uHCC) in a real-world clinical setting
Authors: T. Takehara, N. Kato, H. Aikata, T. Kuzuya, Y. Hiasa, S. Nakamura, K. Yamamoto, N. Morimoto, R. Sakamori, Y. Kawamura, K. Tsuchiya, K. Ueshima, A. Hiraoka, M. Nakano, N. Kokudo, J. Furuse, M. Moriguchi, T. Yamashita, M. Ikeda, M. Kudo
Journal: Annals of Oncology (2024)
303P Cabozantinib versus cabozantinib plus nivolumab in first-line treatment of advanced renal cell carcinoma: A Chang Gung medical foundation multicentric cohort, real-world study
Authors: C-H. Ku, P.J. Su, W-K. Huang, Y-C. Kuo, C-F. Chang, S. Yu
Journal: Annals of Oncology (2024)
143P Claudin-18.2 is a poor prognostic indicator for intrahepatic cholangiocarcinoma
Authors: Y.H. Kuo, K-H. Ong, D-P. Sun, Y-F. Tian, C-L. Chou, T-C. Chan, C-H. Hsing, W-S. Li, C-F. Li, Y-L. Shiue
Journal: Annals of Oncology (2024)
315P Clinical characterization and outcomes of patients with PAX8 positive cancer of unknown primary: A distinct immunophenotypic subset
Authors: J. Allam, J. Zhao, J. Estrella, H. Hwang, V. Higbie, A. Willett, A. Matamoros, E. Lano, K. Raghav, R. Huey
Journal: Annals of Oncology (2024)
239P Adjuvant TACE combined with tislelizumab in patients with resected hepatocellular carcinoma at high risk of recurrence: An open-label, multicenter, phase II trial
Authors: T. Ma, L. Wen, J. Zhang, Z. Zhang, Y. Zeng, Y. Wang, J. Zheng, T. Liang
Journal: Annals of Oncology (2024)
267TiP CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor
Authors: W.P. Yong, Y. Naito, H. Hirano, J. Li, Y. Kurokawa, Y. Komatsu, M. Ozaka, M. Iwatsuki, J-S. Chen, C-C. Yen, J.R. Zalcberg, A.C. Roy, L-T. Chen, Y. Zhou, T. Nishida, T. Doi
Journal: Annals of Oncology (2024)
137P A single-arm, multicenter, phase II study of hepatic arterial infusion chemotherapy (HAIC) combined with donafenib and sintilimab as first-line treatment for unresectable intrahepatic cholangiocarcinoma (CHANCE 2203)
Authors: G. Teng, H. Zhu, J. Song, J. Liu, W. Fan, S. Wang, X. Zhu, W. Lv, Y. Fu
Journal: Annals of Oncology (2024)
159P Spatial organization of B cells in the prediction and prognosis of gastric cancer
Authors: R. Tay, M. Sachdeva, Y.W. Kim, M-C. Kook, H. Kim, J-H. Cheong, G. Schmidt, T. Yoshikawa, T. Oshima, H. Ma, T. Sheng, P. Tan, H.I. Grabsch, R. Sundar
Journal: Annals of Oncology (2024)
320P Patient and clinician priorities and expectations of systemic therapy in metastatic urothelial cancer (mUC)
Authors: C-F. Chan, K. Chan, T.W. Chan, F.Y. Cheung, T.Y. Kam, W.K.P. Kwong, B. Lam, C.M. Lam, H.C.M. Lam, K.S. Law, C. Lee, K.C. Lee, H. Sze, C. Tong, K.C.W. Wong, P. Wu, D.M.C. Poon
Journal: Annals of Oncology (2024)
245P Molecular landscape of neuroendocrine neoplasms using tissue and blood-based genotyping in MONSTAR-SCREEN-2
Authors: S. Ushiyama, Y. Matsubara, T. Hashimoto, M. Saori, S. Kadowaki, N. Okano, K. Ohtsubo, M. Ueno, T. Otsuka, Y. Sunakawa, T. Denda, A. Makiyama, T. Esaki, Y. Kagawa, N. Takahashi, S. Boku, T. Fujisawa, Y. Nakamura, H. Bando, T. Yoshino
Journal: Annals of Oncology (2024)
242P Selective internal radiation therapy with Yttrium-90 (Y-90) resin microspheres for unresectable hepatocellular carcinoma: Experience of a single center in China
Authors: X. Xu, X. Huang, L. Zhang, Y. Liao, M. He, Z. Liang, J. He, X. Wang, Z. He, X. Feng, J. Dong
Journal: Annals of Oncology (2024)
211P Multi-center, retrospective GUIDANCE001 trial comparing TACE with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
Authors: D. Yang, F-J. Zeng, J-L. Nong, J. Liu, H-B. Yao, L. Ye, N. Peng, W-F. Li, P-S. Wu, C. Qin, Z. Su, J-J. Ou, X-F. Dong, Y-H. Yan, T-M. Zhong, M-S. Wu, Y-Z. Chen, G-D. Wang, L. Ma, J-H. Zhong
Journal: Annals of Oncology (2024)
171P A multicenter survey on the administration of adjuvant S-1 chemotherapy for patients with pStage II/III gastric cancer aged 80 years and older
Authors: A. Horinouchi, H. Nomura, M. Yoshino, Y. Kubomura, S. Kimoto, T. Saeki, Y. Ozawa, T. Kikuchi, M. Kaneko, N. Suzuki, S. Naito, R. Kushi, K. Takahashi, H. Imai, S. Oya, S. Tanaka
Journal: Annals of Oncology (2024)
124TiP Safety and efficacy of PD-1 monoclonal antibody with or without mFOLFOX6 neoadjuvant therapy in patients with local advanced deficient mismatch repair/microsatellite instability-high synchronous multiple primary colorectal cancer
Authors: Y. Zhao, F. He, Z. Liu, Q. Yao, F. Pei, J. Huang
Journal: Annals of Oncology (2024)
248P Clinicopathological profile and outcomes of neuroendocrine tumors: Data from a multicenter collaborative registry in India
Authors: S.S. Panda, S. Meedimale, L. Moharana, S. Kayal, B. Dubashi, K.K. Rathnam, S.V. Saju, A. Sehrawat, D. Sundriyal, A. Singh, S.L. Cyriac, A.O. Philips, P. Kinslely, K.B. Priya, D. Halanaik, B. A, K. Raja, S. Bh, S. Natarajan, P. Ganesan
Journal: Annals of Oncology (2024)
277P Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone for previously untreated unresectable or metastatic urothelial carcinoma (u/mUC): Chinese population analysis results from the phase III CheckMate 901 trial
Authors: D. Ye, Z. He, Q. Zou, Z. Wang, D. Xu, P. Zhang, H. Dong, Z. Liu, J. Guo, X. Cao, X. Yuan, J. Chen, Y. Hu, Y-C. Tsai, W. Kang, J. Filian, L. Wang, H. Luo
Journal: Annals of Oncology (2024)
133O Safety of 30 min infusion of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in first-line treatment (tx) of advanced biliary tract cancer (aBTC): TOURMALINE early results
Authors: D-Y. Oh, M. Ikeda, A.R. He, T. Macarulla Mercade, A. Dane, J.O. Park, F. Dayyani, G. Wetherill, A. Stell, B. Baur, P. Sun, A. Vogel
Journal: Annals of Oncology (2024)
340P Rezvilutamide plus androgen deprivation therapy in patients with low-volume, metastatic hormone-sensitive prostate cancer: A national, real-world cohort study
Authors: B. Wang, S. Niu, D. Xia, Q. Zhang, J. Yu, Y. Qi, Q. Chen, L. Mao, H. Liu, Y. Liu, R. Sun, Y. Song, W. Zhang, T. Ruan, S. Zhong, X. Duan, H. Liu, X. Wang, H. Zhang, X. Zhang
Journal: Annals of Oncology (2024)
127O Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Authors: M. Kudo, L. Rimassa, S.L. Chan, B. Sangro, G. Lau, V.V. Breder, M. Varela, O.V. Crysler, M. Bouattour, V.T. Dao, A. Faccio, J. Furuse, L-B. Jeng, Y-K. Kang, R.K. Kelley, M.J. Paskow, M. Makowsky, D. Ran, A. Negro, G.K. Abou-Alfa
Journal: Annals of Oncology (2024)
264TiP A phase Ib/II open-label study evaluating trastuzumab deruxtecan (T-DXd) in combination with rilvegostomig and chemotherapy in patients with HER2-positive (HER2+) and HER2-low gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 Part 4
Authors: Y.Y. Janjigian, C. Lloyd, V.G. de Giorgio-Miller, Y-T. Chang, J. Lee
Journal: Annals of Oncology (2024)
275MO Neoadjuvant sacituzumab govitecan, followed by radical cystectomy, for patients with muscle-invasive bladder cancer (MIBC): Updated interim results of SURE-01 trial
Authors: B.A. Maiorano, A. Cigliola, M. Moschini, V. Tateo, D.A. Patanè, C. Mercinelli, A. Nuccio, G. Latini, M. Borella, G. Brembilla, M. Colecchia, F. Montorsi, A. Necchi
Journal: Annals of Oncology (2024)
778TiP Adjuvant rezvilutamide in combination with androgen-deprivation therapy, with or without radiotherapy, in high-risk patients following radical prostatectomy: A multi-center, open-label, two-cohort exploratory study
Authors: S. Niu, B. Wang, Z. He, Y. Zhang, M. Liu, S. Zhang, Y. Fan, F. Zhang, Z. Zhou, X. Zhao, H. Hou, Q. Zhong, H. Wang, L. Meng, Z. Liu, X. Qi, X. Zhang
Journal: Annals of Oncology (2024)
222P The activity and safety of icaritin for patients with unresectable hepatocellular carcinoma: A real-world, retrospective study
Authors: Z. Hui, G. Shao, Z. Zhang, D. Zhang, J. Luo, W. Jiang, X. Zheng, H. Xiang, S. Wang, X. Zhou, N. Lin, M. Cao, Z. Yu, K. Dong, Q. Xie, C. Liu
Journal: Annals of Oncology (2024)
266TiP The efficacy of tislelizumab combined with S-1 in patients with residual primary lesions and node-negative esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy followed by curative resection: A phase II, multicenter trial (PPIO-008)
Authors: W. Guo, Y. Wang, X. Xie, X. Chen, T. Bao, X. He, J. Yu, K. Li, X. Pu
Journal: Annals of Oncology (2024)
299P Molecular characterization of TFE3-rearranged renal cell carcinoma in pediatric patients and adolescents
Authors: L. Haoyang, H. Liu, J. Chen, X. Yin, S. Zhu, P. Shen, Z. Liu, N. Chen, Y. Chen, H. Zeng, G. Sun
Journal: Annals of Oncology (2024)
199P Impact of baseline tumour burden on outcomes in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
Authors: M. Kudo, R. Lencioni, J. Erinjeri, S.L. Chan, S. Qin, Z. Ren, Y. Arai, J. Heo, V.V. Breder, M. Bouattour, F. Dayyani, J-H. Yoon, C-F. Chiu, T. Suttichaimongkol, T. Decaens, R. Griffin, C. Morgan, S.K. Ali, K. Balaji, B. Sangro
Journal: Annals of Oncology (2024)
203P Epigenetic promoter signatures and ectopic gain of distal intergenic gene regulators contribute to hepatocarcinogenesis: The Planet study
Authors: H-Y. Lin, K. Chen, M. Lee, A-J. Jeon, L. Wu, G. Chen, S. Chong, S-C. Chew, G. Kunnath Bonney, J.H. Kam, B. Goh, R. Foo, P. Chow
Journal: Annals of Oncology (2024)
295P Real-world efficacy and safety of lenvatinib plus pembrolizumab in metastatic renal cell carcinoma patients with intermediate and poor risk
Authors: I. Tsimafeyeu, A.V. Sultanbaev, D.M. Dubovichenko, M. Murzalina, A. Volkov, R.V. Orlova, G. Malina, I. Utyashev, M.I. Gluzman
Journal: Annals of Oncology (2024)
215P Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with portal vein tumor thrombosis (PVTT) treated with camrelizumab, apatinib plus FOLFOX chemotherapy
Authors: L. Peng, T. Chen, Y. Chen, Y. Xu, J. Wang, J. Chen, Y. Li, P. Huang, X. Hu, G. Zhong, X. Chen, C. Ye
Journal: Annals of Oncology (2024)
188P The impact of pathological regression of primary tumor and lymph node on recurrence and survival in patients with locally advanced esophageal squamous cell carcinoma following neoadjuvant chemo-immunotherapy
Authors: Y. Li, Y. Wu, Y. Hong, X. Huang, G. Xiao, B. Yang, L. Gu, L. Zhao, M. Jiang, Y. Xu, Y. Zhao, Y. Chen, Z. Zhu, X. Zhu, N. Jiang
Journal: Annals of Oncology (2024)
240P Efficacy and safety of transarterial chemoembolization (TACE) in combination with tislelizumab and TKIs versus TACE for the treatment of Intermediate and advanced HCC: A retrospective cohort study
Authors: Y. Han, S. Tang, Y. Gao, X. Yan, W. Zhi, T. Gong
Journal: Annals of Oncology (2024)
255P Real-world outcomes of long-term survivors of metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with liposomal irinotecan (nal-IRI) for the Asian cohort of NALLONG study
Authors: C. Yoo, H. Imaoka, T. Okusaka, J.Y. Hong, C-K. Lee, I. Kim, J-L. van Laethem, T. Macarulla Mercade, C.B. Westphalen, G. Prager, F. Hedouin-Biville, B. Chevallier, M. Ueno
Journal: Annals of Oncology (2024)
224P Neoadjuvant therapy versus initial hepatectomy for resectable intermediate or advanced hepatocellular carcinoma (GUIDANCE002): A multicenter, retrospective cohort study
Authors: J-H. Zhong, D. Yang, N. Peng, S. Liu, Y-H. Yan, J-L. Nong, F-J. Zeng, C. Qin, Z. Su, W-F. Li, J. Liu, X-F. Dong, M-S. Wu, H-B. Yao, P-S. Wu, J-J. Ou, Y-Z. Chen, G-D. Wang, L. Ma
Journal: Annals of Oncology (2024)
232P Selective internal radiation therapy with Yttrium-90 (Y-90) resin microspheres for unresectable hepatocellular carcinoma: Experience of a single center in China
Authors: X. Feng, X. Xu, X. Huang, J. He, L. Zhang, Y. Liao, M. He, X. Wang, Z. Liang, Z. He, J. Dong
Journal: Annals of Oncology (2024)
140P Tinengotinib (TT-00420) in combination with atezolizumab (atezo) in Chinese patients (pts) with biliary tract carcinoma (BTC): Efficacy and safety results from a phase Ib/II study
Authors: P. Zhang, J. Gong, Z. Niu, Y. Cheng, B. Cao, X. Hou, J. Fan, P. Peng, C.A. Sun, H. Wang, Y. Yu, Y. Zhu, Q. Li, P. Huang, F. Wu, L. Shen
Journal: Annals of Oncology (2024)
280P Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial
Authors: M. Eto, R.J. Motzer, T.K. Choueiri, J.B.A.G. Haanen, M. Oya, H. Uemura, B. Venugopal, B.I. Rini, H. Miyake, L. Albiges, M. Schmidinger, Y. Tomita, Y. Umeyama, B. Ellers-Lenz, J. Hoffman, J. Larkin
Journal: Annals of Oncology (2024)
134O Asia subgroup overall survival and long-term follow-up results of the phase IIb HERIZON-BTC-01 study: Zanidatamab in previously treated human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC)
Authors: D-Y. Oh, H. Sun, J.W. Kim, H.J. Choi, H-M. Chang, L. Bao, J. Ying, F. Xie, M.A. Lee, Y.M. Seol, X. Wu, Y. Bao, P. Garfin, Y. Zhao, J. Fan
Journal: Annals of Oncology (2024)
138MO Baseline characteristics and molecular testing of patients with IDH1-mutated cholangiocarcinoma: Initial results from the phase IIIb ProvIDHe study
Authors: L. Rimassa, J.A. Bridgewater, A. Casadei-Gardini, H. Wilmink, H-W. Sim, None J. de vos-Geelen, T. Macarulla Mercade, D. Malka, H. Gharbi, R. Robert, A. Sullivan, A. Vogel
Journal: Annals of Oncology (2024)
119TiP A randomized, controlled, multicenter phase III study of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) as neoadjuvant treatment for resectable microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colon cancer
Authors: R-H. Xu, F. Wang, G. Chen, Y. Hu, P-R. Ding, M. Qiu, P. Zhao, Y. Sun, W. Jiang, Z. Song, J. Ma, H. Liu, X. Lu, Q. Guo, H. Zhou
Journal: Annals of Oncology (2024)
292P Avelumab + axitinib (A + Ax) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses by age from the final analysis of the phase III JAVELIN Renal 101 trial
Authors: M. Oya, R.J. Motzer, T.K. Choueiri, J.B.A.G. Haanen, M. Eto, H. Uemura, B. Venugopal, B.I. Rini, H. Miyake, L. Albiges, M. Schmidinger, Y. Tomita, Y. Umeyama, B. Ellers-Lenz, J. Hoffman, J. Larkin
Journal: Annals of Oncology (2024)
324P Pattern of care and long-term outcomes of stage 1 seminoma: Real-world data from the Indian subcontinent
Authors: A. Dhanawat, D. Samaddar, B. Jadhav, A. Tiwari, K.N. Jobanputra, M.J. Shah, N.S. Menon, P. Maitre, M. Pal, A. Arora, A. Ringe, A. Agrawal, S. Menon, G. Prakash, V. Murthy, V. Noronha, K. Prabhash, A.P. Joshi
Journal: Annals of Oncology (2024)
90P Intensity-modulated radiation therapy can reduce acute toxicities in long-course neoadjuvant radiation therapy combined with S-1 for locally advanced rectal cancer
Authors: S. Tatsuno, H. Doi, M. Inada, J. Fukuda, N. Ishida, T. Uehara, K. Nakamatsu, M. Hosono, J. Kawamura, Y. Matsuo
Journal: Annals of Oncology (2024)
139P KEYNOTE-966: 3-year follow-up for pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) vs placebo (pbo) + gem/cis for patients (pts) with advanced biliary tract cancer (BTC)
Authors: M. Ueno, R.S. Finn, C. Yoo, Z. Ren, J. Furuse, R.K. Kelley, S.L. Chan, J. Edeline, H.J. Klumpen, T. Yau, C. Verslype, M. Ozaka, M. Bouattour, J.O. Park, A. Vogel, J.W. Valle, L. Starkopf, U. Malhotra, A.B. Siegel, S. Qin
Journal: Annals of Oncology (2024)
186P Efficacy and safety between weekly and monthly neoadjuvant cisplatin and fluorouracil chemoradiotherapy regimens in locoregional esophageal squamous cell carcinoma
Authors: C-L. Lai, C-H. Lin, H-E. Tzeng, C. Chen, C-Y. Chuang, C-W. Chou
Journal: Annals of Oncology (2024)
96P Liposomal irinotecan + 5-FU/LV + bevacizumab for second-line treatment of metastatic colorectal cancer (IRIS): A prospective, multi-center, single-arm clinical study
Authors: X. Hu, B. Jiang, H. Lu, W. Niu, H. Ma, S. Wang, B. Yi, B. Yu, Y. Chen, C. Lin, B. Li, R. Yang, L. Zhu, D. Kong, Y. Wang, None S. li, W. Zhu, J. Liu, Z. Wang, G. Wang
Journal: Annals of Oncology (2024)
278P Efficacy and safety of cadonilimab plus lenvatinib in previously immunotherapy treated advanced/metastatic clear cell renal cell carcinoma (ccRCC): A multicenter, single-arm, phase II trial
Authors: J. Huang, J. Zhao, X. Hu, W. Kong, Q. Chen, J. Zhang, Y. Chen, J. Guo, D. Xu, W. Xue
Journal: Annals of Oncology (2024)
210P Atezolizumab plus bevacizumab versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma: A large real-life worldwide population
Authors: F. Vitiello, T. Tada, S. Shimose, M. Kudo, J. Cheon, F. Finkelmeier, H.Y. Lim, J. Presa, G. Masi, S. Lonardi, F. Tovoli, M. Scartozzi, E. Tamburini, F.G. Foschi, M. Persano, F. Rossari, S. Foti, S. Camera, A. Casadei Gardini, M. Rimini
Journal: Annals of Oncology (2024)
178P KEYNOTE-859 update: Pembrolizumab + chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
Authors: M.H. Ryu, S.Y. Rha, L.S. Wyrwicz, P.E. Yanez Weber, Y. Bai, J. Lee, F. Rivera Herrero, G.V. Alves, M. Garrido, K-K. Shiu, M. González Fernández, J. Li, M.A. Lowery, T. Cil, F. Cruz, D-Y. Oh, L. Yin, S. Bordia, P. Bhagia, S. Qin
Journal: Annals of Oncology (2024)
100P Treatment outcomes in rectal cancer with radiological positive circumferential resection margin treated with short course radiation therapy
Authors: S. Mahajan, D.K. Simson, V. Antony, A. Pahuja, M. Pansuriya, S. Goel, A. Najeem, S. Mahto, V. Goel, S. Goyal, V. Talwar, S. Singh, M. Gairola, J. Singh Sethi
Journal: Annals of Oncology (2024)
80P Split-course hypofraction radiotherapy combined with chemotherapy and tislelizumab as preoperative treatment for locally advanced rectal cancer: Interim analysis of a prospective, single-arm phase II trial
Authors: R. Zheng, S. Chen, Y. Hong, X. Huang, G. Shi, Z. Chen, L. Wang, Y. Yang, W. Jiang, P. Chi, B. Xu
Journal: Annals of Oncology (2024)
98P Real-world evidence on total neoadjuvant therapy (TNT) vs neoadjuvant concurrent chemoradiation (NA CCRT) for locally advanced rectal cancer (LARC) from a Tertiary Asian Cancer Centre
Authors: M. Wang, Y.X. Gwee, Z. Lin, C.L.F. Ho, F.P. Mok, W.P. Yong, R. Sundar, H.L. Tan, J. Choo, K.K. Tan, B. Lieske, W.K. Cheong, T.H. Tan, J. Tey, C.E. Chee, G. Chan
Journal: Annals of Oncology (2024)
269O Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39
Authors: E. Kikuchi, M.S. van der Heijden, B. Perez Valderrama, S. Gupta, J. Bedke, S.J. Shin, J-R. Li, J. Guo, P. Danchaivijitr, R. Kanesvaran, S.H. Park, W-P. Su, S. Kandori, W.K. Bae, A.S. Wong, J. Lu, X. Yu, A. Shetty, A.A. Bavle, T.B. Powles
Journal: Annals of Oncology (2024)
337MO Efficacy and safety of rezvilutamide (Rez) plus androgen-deprivation therapy (ADT) in patients with high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) aged ≤64, 65–74, and ≥75 years: Post-hoc analysis of randomized phase III CHART trial
Authors: D. Ye, X. Bian, S. Jiang, H. Luo, F. Zhou, D. He, L. Ma, H. Guo, C. Liang, T. Chong, J. Jiang, Z. Chen, Y. Wang, Q. Zou, Y. Tian, J. Xiao, J. Huang, X. Yang, J. Lian, W. Wang
Journal: Annals of Oncology (2024)
262TiP Comparison of adjuvant chemoradiotherapy versus adjuvant chemotherapy in carcinoma gall bladder: A randomized controlled study
Authors: D.K. Das, S.K. Barik, S.K. Das Majumdar, T.S. Mishra, D. Muduly, P. Sasmal, B. Pattnaik, T. Dutta, A. Mishra, H.K. Nayak, R. Patel, T.P. Tripathy
Journal: Annals of Oncology (2024)
225P Real adjuvant transarterial chemoembolization is not associated with good survival in most patients with hepatocellular carcinoma: A multicenter retrospective study
Authors: J-R. Li, J-Y. Su, D-J. Huang, S. Liu, X-L. Xu, J-J. Ou, S-C. Chen, Y-L. Ma, L. Ma, J-H. Zhong
Journal: Annals of Oncology (2024)
130MO EDGE-Gastric Arm A1: Phase II study of domvanalimab (D), zimberelimab (Z), and FOLFOX in first-line (1L) advanced gastroesophageal (GE) cancer
Authors: S.Y. Rha, D-Y. Oh, M. Pelster, Z.A. Wainberg, A. Sison, J. Scott, S. Nelson, D. Wishengrad, J. Rhee, D.S.A. Nuyten, Y.Y. Janjigian
Journal: Annals of Oncology (2024)
151P A new prognostic index for patients with advanced biliary tract cancer treated with cisplatin, gemcitabine and durvalumab
Authors: M. Persano, L. Fornaro, L. Antonuzzo, T. Satake, H. Vandeputte, J. Lucchetti, J.W. Kim, O. Abidoye, I.G. Rapposelli, S. Tamberi, F. Finkelmeier, G. Giordano, F. Nicchetti, H.J. Chon, C. Yoo, S.L. Chan, M. Scartozzi, S. Lonardi, L. Rimassa, A. Casadei Gardini
Journal: Annals of Oncology (2024)
181P The efficacy, safety and cell-free DNA of perioperative leucovorin, oxaliplatin, docetaxel and S-1 (LOTS) for locally advanced gastric or gastroesophageal junction adenocarcinoma: A prospective phase II trial
Authors: C.C. Yen, I.S. Chen, Y.J. Chao, L-Y. Bai, C.Y. Tsai, P. Jui, C.Y. Hsu, T.K. Liao, C-J. Huang, I.T. Liu, Y-S. Shan, C.J. Yen
Journal: Annals of Oncology (2024)
112P Comparative treatment between pembrolizumab and chemotherapy on patients diagnosed with mismatch repair deficient colorectal cancer: A systematic review and meta-analysis
Authors: M.H.H. Wibisono, M.G. Wibisono, M.Z. Sabran, K.J.A. Santoso, J.J. Wibisono, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)